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Fragile X premutation alleles have 55–200 CGG repeats in the 5′ UTR of the FMR1
gene. Altered zinc (Zn) homeostasis has been reported in fibroblasts from >60 years old
premutation carriers, in which Zn supplementation significantly restored Zn-dependent
mitochondrial protein import/processing and function. Given that mitochondria play a
critical role in synaptic transmission, brain function, and cognition, we tested FMRP
protein expression, brain bioenergetics, and expression of the Zn-dependent synaptic
scaffolding protein SH3 and multiple ankyrin repeat domains 3 (Shank3) in a knock-in (KI)
premutation mouse model with 180 CGG repeats. Mitochondrial outcomes correlated
with FMRP protein expression (but not FMR1 gene expression) in KI mice and human
fibroblasts from carriers of the pre- and full-mutation. Significant deficits in brain
bioenergetics, Zn levels, and Shank3 protein expression were observed in the Zn-rich
regions KI hippocampus and cerebellum at PND21, with some of these effects lasting
into adulthood (PND210). A strong genotype × age interaction was observed for most
of the outcomes tested in hippocampus and cerebellum, whereas in cortex, age played
a major role. Given that the most significant effects were observed at the end of the
lactation period, we hypothesized that KI milk might have a role at compounding the
deleterious effects on the FMR1 genetic background. A higher gene expression of
ZnT4 and ZnT6, Zn transporters abundant in brain and lactating mammary glands, was
observed in the latter tissue of KI dams. A cross-fostering experiment allowed improving
cortex bioenergetics in KI pups nursing on WT milk. Conversely, WT pups nursing
on KI milk showed deficits in hippocampus and cerebellum bioenergetics. A highly
significant milk type × genotype interaction was observed for all three-brain regions,
being cortex the most influenced. Finally, lower milk-Zn levels were recorded in milk
from lactating women carrying the premutation as well as other Zn-related outcomes
(Zn-dependent alkaline phosphatase activity and lactose biosynthesis—whose limiting
step is the Zn-dependent β-1,4-galactosyltransferase). In premutation carriers, altered
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Zn homeostasis, brain bioenergetics and Shank3 levels could be compounded by
Zn-deficient milk, increasing the risk of developing emotional and neurological/cognitive
problems and/or FXTAS later in life.
Keywords: bioenergetics, brain, FMR1, milk, mitochondria, premutation, Shank3, zinc
INTRODUCTION
A 55–200 expanded CGG nucleotide repeats in the 5′-UTR of
the fragile X mental retardation one gene (FMR1) constitutes
the genetic hallmark of premutation carriers (OMIM#300623),
whereas >200 repeats give rise to Fragile X syndrome
(FXS; OMIM#300624), the leading inherited form of cognitive
impairment (Kogan et al., 2008; Tassone et al., 2012; Battistella
et al., 2013). Later in life, premutation carriers may have an
increased risk of developing a neurodegenerative disorder known
as Fragile X-associated tremor/ataxia syndrome [FXTAS (Kogan
et al., 2008; Hagerman and Hagerman, 2013)]. Initially, this
prevalent allelic variant was thought to be free of phenotypic
traits; however, neurodevelopmental problems like autism
spectrum disorder (ASD), attention deficit hyperactivity disorder
(ADHD), anxiety, and other types of psychopathologies (Farzin
et al., 2006; Tassone et al., 2012; Winarni et al., 2012; Wong et al.,
2012; Battistella et al., 2013; Chonchaiya et al., 2013) have been
reported in some young carriers, but not as often as in Fragile
X syndrome [i.e., incidence of ASD in FXS is ∼4-fold of that
in premutation carriers (Farzin et al., 2006; Garcia-Nonell et al.,
2008; Harris et al., 2008; D’Hulst et al., 2009; Zingerevich et al.,
2009; Hagerman et al., 2010; Chonchaiya et al., 2013)].
Unlike the full mutation alleles, which undergo repeat-
mediated gene silencing (Pieretti et al., 1991; Sutcliffe et al.,
1992), premutation alleles are active and actually show normal or
elevated FMR1 mRNA levels (Tassone et al., 2000a,b, 2007). It is
still not clearly understood how the premutation pathology arises
and research to date has focused on how premutation alleles
might trigger neurodegeneration through a gain-of-function
(toxicity) RNA mechanism (Tassone et al., 2004; Hagerman and
Hagerman, 2013). It has been suggested that the “excess” of
premutation transcript may bind and sequester factors important
for cell function (Sellier et al., 2010, 2013). Previous work
from our laboratory conducted on fibroblasts from premutation
individuals has shown that zinc (Zn) might also be included
among these factors (Napoli et al., 2011). It has been shown that
while FMR1 gene expression could be high in some carriers,
its product FMRP can be low (Tassone et al., 2000c; Tassone
and Hagerman, 2003) which has been attributed to a reduced
translation efficiency (Tassone and Hagerman, 2003). However,
critical aspects of the pathology cannot be explained purely
by an RNA-mediated process but rather to a protein-mediated
neurodegeneration (Todd et al., 2013). Recently, the paradox
of the RNA- mediated vs. protein-mediated toxicity in FXTAS,
although still controversial (Banez-Coronel et al., 2012), has
been partly explained by demonstrating that CGG repeats trigger
repeat-associated non-AUG-initiated (RAN) translation (Todd
et al., 2013) of a cryptic polyG-containing protein, FMRPolyG.
Accumulation of FMRPolyG has been seen in ubiquitin-positive
inclusions in Drosophila, mammalian cell cultures carrying the
expansion, and brains of patients that died of FXTAS (Todd et al.,
2013) and this lengthy polyglycine tract seems to be toxic to
a number of cell types (Todd et al., 2013; Oh et al., 2015). So
far, the relative contribution of RNA sequestration (of essential
factors), low FMRP expression or RAN translation (of the toxic
FMRPolyG) to the premutation pathology is unknown.
Adding to these mechanisms, bioenergetic deficits with
increased oxidative stress biomarkers have been observed
in post-mortem brain samples (Ross-Inta et al., 2010) and
fibroblasts from premutation carriers (Ross-Inta et al., 2010;
Napoli et al., 2011) and altered mitochondrial dynamics have
been noted in neurons from a knock-in (KI) mouse model of
FMR1 premutation (Kaplan et al., 2012). These deficits seem
to precede the occurrence of ubiquitin-positive intranuclear
inclusions [considered a hallmark of FXTAS; (Greco et al.,
2006)], and correlate with both CGG repeat expansion and
severity of the phenotype (Ross-Inta et al., 2010; Napoli
et al., 2011). Fibroblasts from >60 years old asymptomatic
premutation carriers presented altered protein expression of the
Zn transporters ZnT6/ZnT4 (Napoli et al., 2011) accompanied
by mitochondrial dysfunction (MD; Ross-Inta et al., 2010;
Napoli et al., 2011). This MD was mainly evidenced by
an accumulation of precursor over mature mitochondrial
proteins encoded by the nuclear DNA. This scenario was
significantly reversed upon Zn supplementation, which allowed
Zn-dependent import/processing pathways of nuclearly-encoded
mitochondrial proteins to occur (Napoli et al., 2011).
Abnormal behavior (i.e., over-responsivity and hyperactivity-
like behavior with acute Zn deficiency; ASD-like behavior
secondary to prenatal Zn deficiency) was reported in young
Zn-deficient mice with altered scaffolding elements within the
postsynaptic density of excitatory synapses (Grabrucker et al.,
2014). Indeed, it has been proposed that the ∼50% incidence of
Zn deficiency in children with ASD (Yasuda et al., 2011) has the
potential to contribute to the etiology and/or morbidity of ASD
via dysregulation of the synaptic Shank scaffolding (Grabrucker
et al., 2014). Furthermore, some symptoms of ASD seem to lessen
with Zn supplementation (Russo and Devito, 2011).
Collectively these studies suggest that the FMR1 premutation
affects Zn homeostasis, and that Zn deficits have a detrimental
effect on behavior, opening the door for evaluating the effect of
environmental stressors (such as Zn deficits) at compounding
or initiating MD early in life and, possibly, predisposing young
carriers to develop ASD, ADHD, and/or FXTAS at older age
(Tassone et al., 2012; Winarni et al., 2012; Wong et al., 2012;
Battistella et al., 2013).
Thus, we hypothesized that FMR1 premutation would alter
brain Zn homeostasis, bioenergetics, and protein expression of
Zn-dependent scaffolding protein SH3 and multiple ankyrin
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repeat domains 3 (Shank3), outcomes which could be further
affected by nursing on milk from premutation carriers. To
test our hypothesis, FMR1 gene expression, Fragile X mental
retardation protein 1 (FMRP) protein expression, bioenergetics,
Zn levels, and Shank3 protein expression were evaluated at
post-natal days (PND) 0, 9 (or 7), 21, and 210 in cerebellum,
hippocampus (both areas rich in Zn-containing neurons) as well
as in cortex from a KI premutation mouse model. This murine
model recapitulates some of the molecular, histological, and
neurobehavioral deficits observed in premutation carriers (i.e.,
elevated FMR1mRNA, FMRP protein levels reduced or normal),
and with age they develop intranuclear inclusions in neurons
and astrocytes, ataxia-like mild motor dysfunctions, anxiety, and
cognitive impairments (Hunsaker et al., 2009, 2011, 2012;Wenzel
et al., 2010). To evaluate the effect of carriers’ milk on the
offspring’s brain bioenergetics, a cross-fostering experiment was
designed in which brain mitochondrial function was tested in
suckling WT and KI pups at PND21. To complement the mouse
model studies, Zn and Zn-associated outcomes were evaluated in
breast milk from control and premutation nursing mothers.
Given the key role of Shank3 in post-synaptic neuron
scaffolding and the contribution of mitochondria to the
regulation of synaptic transmission, brain function, and
cognition, we propose that early nutritional Zn interventions
may represent a new preventive strategy in newborns of
premutation mothers with the potential of lowering the risk
of developing emotional or neurological symptoms later in
life, emphasizing the interdependence between genetics and
nutrition.
MATERIALS AND METHODS
Animals
This study was approved by the IACUC Committee at the
University of California Davis, which is accredited by the
American Association for the Accreditation of Laboratory
Animal Care (IACUC-approved protocol number 17896). All
animals were treated accordingly to the guidelines established
by the NIH and the UCD animal welfare committee. Mice were
monitored daily during the length of the experiments. Mice
with signs of stress, weight loss >20%, paralysis, or any other
serious disease, would have been euthanized immediately to
avoid unnecessary pain or discomfort. However, none of the
animals showed these signs of distress or were euthanized. No
animal procedure was attempted without prior approval from
the NIH and the UCD animal welfare committee, as well as
all personnel was trained to handle animals under the current
regulations. Wild-type female C57BL/6J mice were obtained
commercially (Charles River, Wilmington, MA) and the knock-
in (KI) mouse model of the premutation in the same genetic
background (Wenzel et al., 2010) was from Dr. Robert Berman
(University of California, Davis). The mice were housed in
polycarbonate cages and fed ad libitum. Zn content of the diet
used (Purina Pico chow 5058) was 1200 ppm, which with an
average adult body weight of 30 g/mouse and a food intake of
2–5 g/mouse equals to 10–20mg Zn/kg body weight per diem.
Female mice during pregnancy increase their food intake by
about two-fold and during lactation by about four-fold resulting
in 20–40mg Zn/kg body weight per diem during pregnancy and
40–60mg Zn/kg body weight per day during lactation [reference
values= 10mg/kg and 30mg/kg for adult and pregnant/lactating
mice, respectively (Knapka et al., 1974; Luecke and Fraker,
1979; Beach et al., 1982)]. Mice were maintained on a 12 h
light/dark cycle under controlled temperature and humidity.
Mice were bred and allowed to deliver naturally. At PND0, 9 (or
7), 21, and 210, mitochondria were isolated from hippocampus,
cerebellum and cortex from WT and KI male mice (n = 9–
13 at each time point for a total of 54 WT and 55 KI). For
the cross-fostering experiments (performed twice), at birth KI
pups (males; n = 12; CGG repeats = 196 ± 6) and WT pups
(males; n = 12; CGG repeats = 9.3 ± 0.2) were randomly foster-
nursed either on KI dams (173 ± 4 CGG repeats) or on WT
dams, with six pups on each dam. The KI pups were fed with
the same frequency as WT animals. At PND21, WT, and KI
dams were removed from pups for 2 h to control for effects
of suckling on Zn transporter expression and localization, and
subsequently were euthanized by CO2 asphyxiation. Mammary
glands from lactating dams were removed and either snap-
frozen in liquid nitrogen or stored in RNA later. At PND21
pups were also euthanized by CO2 asphyxiation. Euthanasia was
performed by an experienced technician by way of inhalation of
30% CO2 (compressed gas cylinder). This method is considered
acceptable by the 2000 Report of American Veterinary Medical
Association (AVMA) Panel on Euthanasia and it has been
approved by IACUC. The cortex, cerebellum, and hippocampus
were removed post-mortem and processed immediately to isolate
mitochondria.
Isolation and Purification of Mitochondria
from Brain Regions
Enriched mitochondrial fractions were obtained from cortex,
cerebellum and hippocampus at PND0 (n = 13 WT and 13
KI), PND7 (n = 9 WT and 9 KI), PND21 (n = 12 WT and
12 KI), and PND210 (n = 11 WT and 12 KI). Intact, highly
purified, non-synaptosomal mitochondria from the same brain
tissues were isolated through a Percoll gradient as previously
described in detail (Napoli et al., 2012, 2013), resuspended in
iso-osmotic 150 mM KCl and immediately used for oxygen
consumption measurements. Western blots to actin (cytosolic
protein) and beta-ATPase (mitochondrial protein) showed a
cytosolic contamination of themitochondrial fraction of less than
2% [see (Napoli et al., 2013)].
Primary Neuronal Cultures
To assess the contribution of glia to brain mitochondrial
outcomes [as previously shown in Napoli et al. (2012)], isolated,
intact primary neurons were obtained from WT and KI pups
at PND0, using an established methodology (Brand, 1990;
Jekabsons and Nicholls, 2004). Cultures of dissociated neurons
were prepared as described in Kaplan et al. (2012) and kindly
provided by Dr. Eitan Kaplan. Intact (non-permeabilized)
neurons suspended in PBS supplemented with 10 mM glucose
were used for evaluation of oxygen consumption followed by
sequential additions of 5 µg/ml oligomycin and 20 µM FCCP
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(Napoli et al., 2011). The RCR under uncoupling conditions or
RCRu in intact cells was calculated as the oxygen uptake ratio of
State 3u (with FCCP) over that of oligomycin-induced State 4.
Mitochondrial Outcomes
Enriched mitochondrial fractions or in intact, purified
mitochondria were used for evaluation of oxygen consumption
using a Clark-type oxygen electrode (Hansatech, King’s Lynn,
UK) as described (Napoli et al., 2013). An aliquot (0.1–0.3mg
protein/ml) of mitochondria was added to the oxygen chamber in
a buffer containing 0.22 M sucrose, 50 mM KCl, 1 mM EDTA, 10
mMKH2PO4, and 10 mMHEPES, pH 7.4. Oxygen consumption
rates were evaluated in the presence of (i) 1 mM ADP plus 1
mM malate–10 mM glutamate followed by the addition of 5
µM rotenone; (ii) 10 mM succinate followed by the addition of
10 mM malonate; (iii) 10 mM α-glycerophosphate followed by
addition of 3.6 µM antimycin A; and (iv) 10 mM ascorbate and
0.2 mM N,N,N′,N′-tetramethyl-p-phenylenediamine followed
by the addition of 1 mM KCN. The activities of mitochondrial
NADH oxidase, succinate oxidase, and cytochrome c oxidase
were evaluated as the difference of oxygen uptake recorded
before and after the addition of rotenone, malonate, antimycin
A, and KCN respectively, and normalized by the activity of
citrate synthase (a marker of mitochondrial mass). Citrate
synthase activity was evaluated spectrophotometrically as
described elsewhere (Napoli et al., 2013) using 1–2 µg of
mitochondrial protein. The respiratory control ratio (RCR)
with malate/glutamate as a substrate was calculated as the ratio
between oxygen uptake rates in State 3 (with ADP or under
phosphorylating conditions) and State 4 [rotenone-resistant
oxygen uptake or non-phosphorylating conditions; (Napoli et al.,
2013)].
Western Blots
For quantification of FMRP, Shank3, cytochrome c oxidase
subunit IV (CCOIV), ATPase β-subunit (ATPB), β-actin,
GAPDH, and tubulin expression levels, brain regions
(hippocampus, cerebellum, and cortex) at PND9, 21, and
210 from WT and KI mice were homogenized in cold 20 mM
HEPES, pH 7.4, added with protease and phosphatase inhibitor
cocktails (Sigma, St. Louis, MO), and centrifuged at 13,000 × g
for 10min to eliminate particulate matter. A second set of Shank3
immunoblots (shown in Supplementary Figure 1) was carried
out by using acetone precipitation to concentrate and partly
delipidate the samples as previously described (Fujisawa et al.,
2015). Thirty to fifty microgram of proteins were solubilized in
SDS sample buffer (Life Technologies, Grand Island, NY) and
loaded onto a 4–12% bis-tris gel (Life Technologies) as previously
described (Napoli et al., 2013). After transferring proteins with
an iBlot apparatus (Life Technologies), membranes were blocked
with LI-COR blocking buffer (LI-COR Biosciences, Lincoln,
NE) for 1 h at room temperature and subsequently probed with
anti-FMRP antibody (Sigma, St. Louis, MO; 1:700 dilution),
anti-Shank3 antibody (Santa Cruz Biotechnologies, Dallas, TX;
1:500 dilution), anti-CCOIV antibody (Cell Signaling, Danvers,
MA, 1:1000 dilution), anti ATPB (BD Biosciences, San Jose, CA,
1:3000 dilution) overnight at 4◦C, and with anti-β-actin (Sigma,
St. Louis, MO; 1:20,000 dilution) for 1 hour at room temperature.
Tubulin (Proteintech, Chicago, IL; 1:1,000 dilution) and GAPDH
(Santa Cruz Biotechnology, Dallas, TX, 1:300 dilution) were used
as loading controls. Secondary antibodies were from LI-COR
(Lincoln, NE; 1:10,000 dilution). Membranes were visualized
with the use of the Odyssey Infrared Imaging System (LI-COR)
and densitometry analysis carried out with the Carestream
software (Napoli et al., 2013).
Gene Expression of ZnT4/T6 In Mammary
Glands from Lactating WT and KI Dams
RT-qPCR performed with three different sets of commercially
available primers from Life Technologies showed low specificity
and efficiency. Thus, the gene expression of ZnT4 and ZnT6 was
assessed by PCR. Total RNA was isolated from homogenized
mammary gland following the manufacturer’s instructions
(Qiagen). Concentration and purity of RNA was measured at an
absorbance of 260 nm and 280 nm using the Tecan i-control
1.6 software (v.1.6.19.2) on Tecan infinite M200 Nanoquant
(Tecan, Austria). Following RNA isolation, 2 µg of the RNA
was used to make cDNA with the Qiagen Quantitech RT
Kit following the manufacturer’s instructions. Following cDNA
synthesis, ZnT4, and ZnT6 gene expression was performed
by Touchdown PCR in a 96-well plate in a 25 µl reaction
volume containing: 100 ng of cDNA, 2.5 µl of 10x Advantage
2 PCR buffer (Clontech, Mountain View, CA), 0.5 µl of 50X
Advantage 2 Polymerase Mix (Clontech), 1 µl of 10 mM
dNTPs (Life Technologies, Grand Island, NY), and 0.5 µl
of each 10 mM forward and reverse primer. Mouse primers
for ZnT4 were: forward 5′-CTCCAGGCCGACGATGACT-
3′; reverse 5′-GTGTCCACTAGATACCATGCTTGG-3′. Primers
for ZnT6 were: forward 5′-CAGACCTTAGCCGCAGCTTG-
3′; reverse 5′-GGTCTGAGAAGTTTAGGACGTTGG-3′. PCR
cycling parameters were: 95◦C for 3 min; 10 cycles of: 94◦C for
15 s, 65◦C for 30 s (with 1◦C decrease at each cycle), and 72◦C
for 40 s; 30 cycles of: 95◦C for 15 s, 55◦C for 30 s, and 72◦C for
40 s; 5 min at 72◦C, 15◦C hold step. PCR was performed on a
Mastercycler EP Realplex thermocycler (Eppendorf, Westbury,
NY). PCR products were separated in a 1.3% agarose gel in
the presence of ethidium bromide, and the fragments had the
expected sizes of 585 bp (ZnT4) and 537 bp (ZnT6). Gene
expression of ZnT4 and ZnT6 was normalized by that of GAPDH.
Expression of GAPDH was performed in a 96-well PCR plate
by Real Time RT PCR with 100 ng of cDNA, TaqMan Universal
PCR Mastermix (Life Technologies, Grand Island, NY), and 0.5x
GAPDH primer-probe mix (Life Technologies, Grand Island,
NY). Amplification was performed using the default cycling
parameters of 2 min at 50◦C, 10 min at 95◦C, and 40 cycles of
15 s at 95◦C, and 60 s at 60◦C. PCR product was separated in a 3%
agarose gel electrophoresis in the presence of ethidium bromide
with an expected fragment size of 107 bp.
Human Subjects and Breast Milk Samples
Control breast milk samples were obtained from 25 healthy
women who gave birth to healthy term infants enrolled in
the UC Davis Foods for Health Institute Lactation Study
(ClinicalTrials.gov Identifier: NCT01817127). Donors filled out
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detailed health history questionnaires regarding demographics,
anthropometrics, pregnancy history, current, and prior health
history, current dietary intake habits and restrictions, physical
activity level, as well as medication and supplementation intake
history during the third trimester of pregnancy and 1 year
postpartum. Half of the control donors reported intake of
prenatal vitamins and minerals during the post-partum period.
Breast milk was also obtained from one control and five
premutation lactating mothers seen through the Fragile X
Treatment and Research Center at the M.I.N.D. Institute at
the University of California Davis Medical Center. All milk
samples (5–30 ml) were obtained between 8 and 20 lactation
weeks. These women delivered their infants between 38 and 41
weeks of gestation. Fresh milk samples were collected using hand
expression at the conclusion of a morning breastfeed (between
09.00 and 12.00 h). All milk samples were frozen within 1 h of
expression at –20◦C, and transferred to –80◦C until analyzed.
Genotyping for these individuals was performed by extracting
gDNA from milk samples and following the procedure described
before (Tassone et al., 2012). The UC Davis Institutional Review
Board approved all aspects of the study (IRB # 200917212-1) and
informed consent was obtained from all donors.
Activity of Milk Alkaline Phosphatase
ALP activity was measured in breast milk and the method
optimized using unpasteurized cow’s milk (from Trader Joe’s,
Davis, CA). ALP activity was evaluated in 6 µl (correspondent
to ∼12–13 µg of protein) of breast milk samples using the
QuantiChromTM Alkaline Phosphatase Assay Kit (BioAssay
Systems, Hayward, CA). The assay utilizes p-nitrophenyl
phosphate that is hydrolyzed by ALP into a color product, which
is measured at λ = 405 nm for 5 min at 37◦C. Total protein
concentration of breast milk was measured with the Pierce
BCA Protein Assay kit (Thermo Scientific, Waltham, MA). ALP
activity was expressed either asµmol× (min× l milk)−1 or nmol
× (min × mg protein)−1. The detection limit of this assay was
(mean ± SEM) 0.050 ± 0.001µmol × (min × l)−1 (n = 16) and
the inter-assay CV was 8.1% (n= 32).
Milk Lactose Determination
Lactose was determined by an enzymatic spectroscopic method
according to the manufacturer’s instructions (Biovision, Milpitas,
CA). The recovery of a known amount of lactose added to the
milk samples was (mean ± SEM) 101 ± 0.9 % (n = 12). The
detection limit of this assay was 0.025 ± 0.002 nmol galactose
(n= 12) and the inter-assay CV was 10.2% (n= 42).
Determination of Zn Levels in Murine Brain
and Human Milk
Measurements of Zn in murine brain regions and human milk
were carried out with the Zn fluorophore zinquin (Sigma-
Aldrich, St. Louis, MO) essentially as previously described
(Zalewski et al., 2006) with some modifications. To evaluate
total Zn levels in mouse brain regions, homogenized samples
for Western blot analysis were used. One-hundred microgram of
brain protein was added to each well of a 96-well-microplate to a
final volume of 100µl in the presence of 10µMzinquin dissolved
in Zn-free Hank’s balanced salt solution (HBSS, in mM: 0.03
Na2HPO4, 0.4 KH2PO4, 4.2 NaHCO3, 5.4 KCl, 5.6 D-glucose,
137 NaCl; pH 7.4) following the addition of Zn-free ovalbumin
to a final concentration of 0.3 mg/ml (to prevent precipitation
of the lipophilic zinquin from aqueous solutions). Samples were
incubated in the dark for 40 min at 22◦C, and fluorescence was
evaluated at excitation and emission wavelengths of 365 and 510
nm, respectively.
For the determination of Zn in milk, 5 µl of milk were
used and the assay carried out essentially as described for brain
samples, but with and without 10 mM EGTA. EGTA-containing
samples were used to obtain the non-labile Zn fluorescence,
as EGTA removes any free Zn-related fluorescence. Free Zn
concentrations were evaluated by subtracting the fluorescence in
the presence of EGTA by the total fluorescence without EGTA,
and converting fluorescence values into Zn concentrations using
the linear part of a calibration curve performed with 1 to 25
µM ZnSO4.To confirm that milk or brain samples did not
display any intrinsic fluorescence at the excitation and emission
wavelengths used, blanks without zinquin were prepared. No
unspecific fluorescence was recorded in any of the samples in the
absence of zinquin.
Human Fibroblasts Collection and
Outcomes
Skin biopsies from controls, premutation and full mutation
carriers were obtained from subjects recruited through the
Fragile X Treatment and Research Center at the M.I.N.D. at
the University of California Davis Medical Center. The UC
Davis Institutional Review Board approved all aspects of the
study and informed consent was obtained from the parents of
the children. All fibroblasts were grown in Minimum Essential
Medium (MEM) supplemented with 15% FBS, 2 mM glutamine
and 1 mM sodium pyruvate. FMRP levels were evaluated by
Western blots upon lysis of whole cells in RIPA (25 mM
MOPS, 150 mM NaCl, 1 mM EDTA, 1% Triton, 0.1% SDS,
and 1% DOC, pH 7.5), and centrifugation at 12,000 × g for
10 min. For FMR1 gene expression, RNA was isolated from
106 fibroblasts using the RNeasy Plus Mini Kit from Qiagen
(cat. no. 74134) following the manufacturer’s protocol. cDNA
was synthesized from the RNA using Qiagen’s Quantitect RT
kit following manufacturers recommendations. RNA and cDNA
concentrations were determined using the Tecan Infinite M200
Nanoquant plate reader (Tecan, Austria). Primer/probe mix was
purchased from Life Technologies (Grand Island, NY, USA)
for FMR1 and XRCC5 (housekeeping gene) were also obtained
by Life Technologies. Sequences of commercial primers and
probes are proprietary. cDNA was diluted to 5 ng/µl and served
as stock template for QRTPCR. QRTPCR was performed in a
Mastercycler EP Realplex thermocycler (Eppendorf, Westbury,
NY). Amplification was performed using the following cycling
parameters: 2 min at 50◦C, 95◦C for 10 min, followed by 40
cycles of 15 s at 95◦C and 1 min of at 60◦C. The mean cycle
time was obtained by double derivatives (CalqPlex algorithm;
Eppendorf, Westbury, NY) and designated as Ct. Each sample
was analyzed in triplicates, and positive and negative controls
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were run on each plate. Coefficient of variation (CV) was
0.3% or less on average. The gene expression of FMR1 was
determined by the comparative Ct method using the following
equation: 21Ct, where 1Ct = CtTarget–CtHousekeeper. The gene
expression fold change (premutation or full muation/Control)
was determined using the 11Ct method using the following
equation: 2(1CtFXTAS−1CtControl). Fold changes were calculated
based on their age matched controls. Values were converted
to positive or negative values to indicate up or down gene
regulation. Coupling between electron transport and ATP
production were tested in whole, intact cells as previously
described (Napoli et al., 2011).
Statistical Analysis
Data are expressed as mean ± SEM. Statistical analysis was
performed either by Student’s t-test (for comparisons between
WT and KI), or by Two-way ANOVA, followed by the Tukey’s
HSD post-hoc test for multiple comparisons with the GraphPad
Prism 6.0 software (San Diego, CA). Significance was set at p ≤
0.05. Unless otherwise noted, experiments were run in triplicates
(technical replicates) and performed at least in 2–3 separate
occasions (biological replicates). To determine the minimum
number of mice/group, we used an a priori G test (software
STATsimple; v. 2.0.5) with selected mitochondrial outcomes that
indicated 4 mice as optimal given an alpha of 0.05 with an
actual power of 0.993. Considering the yield of mitochondria
from mouse brain (a limiting step), sample needed for assay in
triplicates, and the assay parameter (polarography) that requires
the largest amount of sample, 5 mice/group were used at a
minimum for each time point, unless otherwise stated.
RESULTS
Decreased FMRP Protein Levels in Brain
from Young KI Mice
Male, hemizygous KI mice were used as a murine model of the
FMR1 premutation [CGG repeat expansion = 196 ± 6; (Wenzel
et al., 2010)]. This model recapitulates most deficits observed in
premutation carriers (Hunsaker et al., 2009, 2011, 2012; Wenzel
et al., 2010). Despite the relatively high CGG expansions, the
expression of the FMR1 gene product FMRP, was still detectable
at PND9, PND21, and PND210 in hippocampus, cerebellum,
and cortex and not absent as observed in models of Fragile X
syndrome [(Zalfa et al., 2003); Figures 1A,B]. Consistent with
other reports (Ludwig et al., 2014), FMRP protein expression
decreased with age in all brain areas in WT (Figure 1B);
conversely, no age-dependent effect was observed on FMRP
expression of KImice in any of the brain regions tested. At PND9,
40-50% of FMRP control values were observed in hippocampus,
cerebellum, and cortex of KI mice, effect that lasted into PND21
for the first two tissues (Figure 1B).
Interestingly, in all three-brain regions the expression levels
of FMRP were followed by those of β-actin (Figure 1C). The
correlation between actin and FMRP protein levels is consistent
with the role of FMRP as regulator of actin filaments organization
and dynamics (Castets et al., 2005; Nolze et al., 2013), a
key process in the morphogenesis of dendritic spines (Castets
et al., 2005), influencing the effect of actin on mitochondria
distribution and function (Kusano et al., 2000; Xu et al.,
2001; Dugina et al., 2009), mitochondrial fission (Korobova
et al., 2013; Hatch et al., 2014; Li et al., 2015), short-
distance mitochondrial movements (Boldogh and Pon, 2006),
mitochondria quality control (Higuchi et al., 2013), mitochondria
clustering and reactive oxygen species (ROS) generation
(Li et al., 2004).
Deficits in Bioenergetics in Brain Regions
from Young KI Mice
Different segments of the electron transport chain from brain
mitochondria (hippocampus, cerebellum, and cortex) were tested
for their capacity to generate ATP in WT and KI mice:
NADH oxidase (using NAD-linked substrates such as glucose
and comprising Complex I, III, IV, and V), succinate oxidase
(using FAD-linked substrates such as fatty acids and comprising
Complex II, III, IV, and V), as well as citrate synthase activity
as a normalizing marker of mitochondrial mass. Complex IV, or
cytochrome c oxidase (CCO), activity, and coupling betweenATP
synthesis and electron transfer (as judged by the RCR) were also
tested.
At PND0-7, no statistically significant differences were
observed in mitochondrial outcomes between WT and KI pups
in any of the brain regions tested (Figure 2). At PND21,
hippocampus was the most affected brain area in KI pups, with
significant decreases in NADH oxidase, succinate oxidase, and
CCO activities, as well as increased uncoupling between ATP
production and electron transfer, relative to WT (Figure 2).
At PND21, uncoupling was also evident in cerebellum of KI
pups, but to a lesser extent than hippocampus (Figure 2),
whereas in adult age (PND210) succinate oxidase, and coupling
(hippocampus) were still significantly lower in KI hippocampus
than age-matched WT mice. No difference was observed in any
of the outcomes in cortex at any of the time points (Figure 2).
Mitochondrial protein levels (relative to total protein) were
evaluated by measuring the expression of the abundant protein
ATPase β-subunit of Complex V [ATPB; (Elfering et al., 2004;
Haynes et al., 2010), Figure 3]. Lower levels of ATPB were
noted at PND21 and lasting into adulthood (PND210) in
hippocampus of KI mice, while in cerebellum significant ATPB
deficits were observed only at PND21 (Figure 3). No statistically
significant differences were observed in cortex at any time point
(Figure 3).
Taken together, these results point toward a generalized
OXPHOS deficit in premutation pups’ hippocampus,
characterized by lower ATP production with both NAD-
and FAD-linked substrates, accompanied by lower expression of
ATPB. These deficits were less evident in cerebellum (uncoupling
and lower ATPB expression were evident at PND21 only), with
no apparent involvement of cortex.
The OXPHOS changes observed in brain mitochondria
could not be ascribed to a specific subcellular localization
(e.g., synaptosomal mitochondria derived only from the termini
of neurons vs. free, non-synaptosomal mitochondria) because
the majority of brain mitochondria [88% of all mitochondria
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FIGURE 1 | Changes in FMRP protein expression in brain from WT and KI mice. (A) Representative Western blots of FMRP and actin protein expression levels
in hippocampus and cortex of WT and KI mice. Tubulin was used as loading control. FMRP protein levels of KI mice hippocampus and cerebellum were 37 and 45%
of WT at post-natal day (PND) 9, and 41 and 50% of WT at post-natal day 21. In cortex, FMRP protein levels in KI mice were 38% of WT at post-natal day 9. (B)
Time-dependent changes in FMRP protein levels in hippocampus, cerebellum, and cortex respectively. Data are reported as mean ± SEM, n = 3–5 per genotype per
time point. Statistical analysis was performed by Two-way ANOVA. Post-hoc analysis performed by Tukey’s HSD test revealed significant differences between WT and
KI, indicated in the figure by asterisk as follows. Hippocampus: ****p < 0.0001; Cerebellum: *p = 0.0110; Cortex: **p = 0.0003, *p = 0.0363, ***p = 0.0001.
Statistically significant differences among time points are indicated by letters with the following p values. p = 0.0029 (a), p < 0.0001 (b), p = 0.0009 (c), p = 0.0260
(d), p = 0.0101 (e), p = 0.0033 (f ), p = 0.0020 (g). For more statistical details on the genotype, age, and genotype × age effect see Table 3. (C) Correlation between
FMRP and actin in the same brain areas. AUD, Arbitrary Units of Densitometry.
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FIGURE 2 | Brain bioenergetics of KI mice during neurodevelopment and adulthood. Mitochondria were isolated from cortex, cerebellum, and hippocampus
of WT and KI pups as described in the Methods section. Activities of NADH oxidase, succinate oxidase, and cytochrome c oxidase (CCO), and respiratory control
ratio (RCR) were evaluated at PND0 (cerebellum and cortex only, due to the scarcity of hippocampal tissue), PND7, PND21, and PND210. Data are reported as mean
± SEM, n = 3–7 per genotype per time point. Statistical analysis was performed by Two-way ANOVA. Post-hoc analysis performed by Tukey’s HSD test revealed
significant differences between WT and KI indicated by asterisks as follows NADH oxidase: *p = 0.0468; Succinate oxidase: *p = 0.0466 at PND21, *p = 0.0423 at
PND210; Cytochrome c oxidase: *p = 0.0484; Coupling: **p = 0.001, ***p = 0.0004, *p = 0.0496. Letters indicate statistically significant differences amongst time
points as follows. NADH oxidase: p = 0.0291 (a), p = 0.0033 (b), p = 0.0166 (c), p = 0.0320 (d), p = 0.0036 (e), p = 0.0001 (f ), p = 0.0113 (g), p = 0.0032 (h), p =
0.0004 (i); Succinate oxidase: p <0.0001 (a), p = 0.0002 (b), p = 0.0240 (c), p = 0.0434 (d), p = 0.0283 (e), p = 0.0009 (f ), p = 0.0250 (g), p = 0.0013 (h);
Cytochrome c oxidase: p = 0.0053 (a), p = 0.0035 (b). Coupling: p = 0.0003 (a), p = 0.0010 (b). Further statistical details on the genotype, age, and genotype × age
effect can be found in the legend of Table 3.
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FIGURE 3 | Protein expression levels of mitochondrial ATPase β-subunit in brain from KI mice. ATPase β-subunit protein expression (normalized to GAPDH)
was evaluated at PND9, 21 and 210 in hippocampus, cerebellum, and cortex lysates. Asterisk in the immunoblot image of hippocampus denotes a 90 CGG KI
sample. Densitometry data for this sample have not been taken into account for averages calculation of KI. Cortex samples were ran in two different gels (PND9 and
PND21-210) and are shown separately. Data are reported as mean ± SEM, n = 3–5 per genotype per time point, ran in triplicates. Statistical analysis was performed
by Two-way ANOVA. Post-hoc analysis was performed by Tukey’s HSD test for multiple comparisons. Significant difference between WT and KI are indicated by
asterisks as follows. ****p < 0.0001; *p < 0.0492. Statistically significant differences among time points are indicated by letters as follows: p < 0.0001 (a, c), p =
0.0087 (b), p = 0.0222 (d). Further, statistical details on the genotype, age, and genotype × age effect can be found in Table 3. AUD, Arbitrary Units of Densitometry.
(Rendon and Masmoudi, 1985)] are non-synaptosomal (Napoli
et al., 2012). As such, no OXPHOS differences were observed
between mitochondria-enriched fractions and highly purified,
non-synaptosomal mitochondria at PND21 in any brain region
fromWT and KI (Table 1).
Isolated Neurons Recapitulate the
Mitochondrial Deficits Observed in KI
Brain Regions
Non-synaptosomal mitochondria as well as mitochondria-
enriched fractions are, by necessity, removed from their
cytoplasmic environment with the potential of altering their
function through the purification process. To address this
issue, in parallel we tested mitochondrial function in a system
retaining cellular specificity and with an intact intracellular
milieu. OXPHOS was directly evaluated in isolated, intact
hippocampal, cerebellar, and cortical neurons obtained from 4–6
pooled WT and KI mice at PND0 (Table 2). Glucose-sustained
basal respiration of intact neurons, followed by the addition of
the ATPase inhibitor oligomycin, was recorded to establish the
ATP production linked to oxygen uptake. Subsequent addition
of FCCP, an uncoupler of ATP production and electron transfer,
allowed evaluating the maximum mitochondrial oxygen uptake
capacity. ROS-mediated oxygen uptake and membrane proton
leak (oligomycin-resistant oxygen uptake rates), oxygen uptake
linked to ATP production (oligomycin-sensitive), and spare
respiratory capacity (FCCP-mediated maximal respiration rate)
were expressed as a fraction of the basal oxygen consumption rate
for both WT and KI neurons (Table 2). At PND0, a deficiency in
the ATP-driven oxygen uptake was already evident in isolated KI
Frontiers in Neuroscience | www.frontiersin.org 9 April 2016 | Volume 10 | Article 159
Napoli et al. FMR1-Premutation, Zinc, Bioenergetics, Autism, Breast-Milk
TABLE 1 | Comparison of outcomes in mitochondria-enriched fractions vs. purified, non-synaptosomal mitochondria from cerebellum and cortex at
PND21 in WT and KI mice.
Outcomes Cerebellum Cortex
Total Non-synaptosomal Total Non-synaptosomal
mitochondria mitochondria mitochondria mitochondria
WT KI WT KI WT KI WT KI
OXYGEN UPTAKE RATES
NADH oxidase 5.38 ± 0.01 4.5 ± 0.3 52.4 ± 1.3 58.3 ± 5.6 8.8 ± 3.3 8.4 ± 1.0 50 ± 11 45 ± 6
Succinate oxidase 6.31 ± 0.02 2.33 ± 0.01** 47.1 ± 1.0 26 ± 2** 8.1 ± 0.8 6.5 ± 1.0* 74 ± 15 45 ± 2*
ACTIVITIES
Cytochrome c oxidase 14.3 ± 0.1 10 ± 1** 168 ± 28 116 ± 19** 27 ± 1 16 ± 1** 149 ± 17 64 ± 4**
Citrate synthase 274 ± 52 293 ± 31 2314 ± 305 2400 ± 320 263 ± 27 282 ± 39 2258 ± 360 2324 ± 199
All activities were expressed as nmol oxygen consumed × (min × mg protein)−1. Citrate synthase was expressed as nmol × (min × mg protein)−1.
Statistical analysis was carried out with the Student’s t-test. The p-values are as follows: *< 0.05, **< 0.01.
TABLE 2 | Mitochondrial coupling and respiratory capacity in intact, isolated neurons from WT and KI mice at PND0.
Outcomes Hippocampus Cerebellum Cortex
(% Basal rate)
Oxygen consumption rates WT KI WT KI WT KI
Oligomycin-sensitive 90 ± 1 85 ± 1** 89 ± 3 80 ± 6 84 ± 2 77 ± 3
Oligomycin-resistant 0.33 ± 0.33 6.9 ± 0.5*** -0.22 ± 0.22 0.9 ± 0.2* 3 ± 5 19 ± 3*
Spare respiratory capacity 128 ± 12 62 ± 2** 102 ± 30 74 ± 42 110 ± 17 67 ± 12
Coupling Hippocampus Cerebellum Cortex
RCRu 11 ± 2 3.4 ± 0.8* 9 ± 1 1.7 ± 0.4** 7 ± 1 0.9 ± 0.3***
Oxygen consumption rates under basal conditions (in the presence of glucose only) were not statistically significant different between WT and KI in any of the brain regions [average
of WT and KI = 6.5 ± 0.7; 3.4 ± 0.9; and 3.1 ± 0.5 nmol oxygen consumed × (min × 106 cells)−1 for cortex, cerebellum and hippocampus, respectively]. Oxygen uptake linked to
ATP production (oligomycin-sensitive mitochondrial oxygen uptake), ROS-mediated oxygen uptake and membrane proton leak (oligomycin-resistant mitochondrial oxygen uptake), and
spare respiratory capacity (FCCP-mediated maximal respiration rate) were expressed as a fraction of the basal oxygen consumption rate. The RCRu represents the ratio between FCCP
and oligomycin-resistant oxygen uptake rates. Data (from three separate preparations run in duplicates) are shown as mean ± SEM. Statistical comparison between WT and KI was
performed with the Student’s t-test. The p-values are as follows: *< 0.05; **< 0.005; ***< 0.0005.
hippocampal neurons, consistent with this area being the most
affected.
Interestingly, KI neurons show a dramatically lower
spare respiratory capacity than WT, capacity defined as the
mitochondrial ability to meet increased energy demand with
increased respiration (Table 2). This may indicate a lower
capacity to adapt to stressful situations with increased ATP need.
The coupling (as judged by the RCRu) and the oligomycin-
resistant oxygen uptake were significantly different (3–5-fold
lower and 4–20-fold higher, respectively, than controls) in KI
compared to WT in all brain areas (Table 2). The lower RCRu
and spare respiratory capacity of hippocampal KI cells are of
significant biological relevance because energy deficits generated
by an imbalance between bioenergetic reserve and demand, play
a critical role in the survival of neurons under stress conditions
(Nicholls, 2008) and can lead to disrupted synaptic network
(Selkoe, 2002; Yadava and Nicholls, 2007).
The apparent discrepancy between the marked deficits
observed at PND0 in KI isolated neurons (Table 2) relative to the
ones at PND7 in KI non-synaptosomal mitochondria (Table 1)
or total mitochondrial fractions (Figure 2) can be bridged taking
into account the absence of supporting cells (glia) in a neuron-
only culture system (Iwata-Ichikawa et al., 1999; Bélanger and
Magistretti, 2009), which could be even more critical for neurons
with an already compromised genetic background. Alternatively,
neuronal mitochondria might be more affected than those of glia,
masking the effect when both are tested in mitochondria-rich
fractions from brain.
Coupling Between Electron Transport and
ATP Synthesis Correlates with FMRP But
Not FMR1 Expression Levels In Human
Fibroblasts
As a proof of concept, to test whether FMR1 gene or FMRP
protein expression influence mitochondrial outcomes, we turned
to human primary skin fibroblasts from premutation and full
mutation carriers, as commercially available FMR1 KO mice are
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FIGURE 4 | Correlation between mitochondrial outcomes and FMRP or FMR1 expression levels. The correlation between FMRP and FMR1 expression with
a mitochondrial outcome (i.e., coupling between ATP synthesis and electron transfer or RCRu) was carried out using human primary dermal from controls,
premutation carriers (105–180 CGG), and full mutation carriers (>200 CGG repeats). RCRu, FMR1, and FMRP levels were expressed as percentage of control values.
Data are shown as mean ± SEM for controls, permutation, and full mutation carriers.
on a different genetic background (FVB129 or FVB129/NJ) than
the ones used in this study (C57BL/6J) making the comparison
invalid [see as an example for Huntington’s disease, another
triplet-nucleotide repeat disease (Menalled et al., 2009)]. In
addition, KO mice may not recapitulate the full mutation
seen in humans, since humans show no expression of FMRP
over time as a result of a repeat-mediated gene silencing
sometime during early development (Pieretti et al., 1991; Sutcliffe
et al., 1992). To this end, FMR1 and FMRP expression were
assessed in fibroblasts from controls, premutation (105–180
CGG matching the range of CGG in KI mice), and full
mutation (>200 CGG repeats) carriers (Figure 4). Fibroblasts
from premutation carriers showed normal or marginally elevated
FMR1 transcript levels with ∼50% FMRP levels of controls; in
contrast, fibroblasts from full mutation carriers showed no gene
or protein expression. When the link between FMR1 and FMRP
expression and bioenergetics (as judged by coupling between
ATP synthesis and electron transfer, RCRu) was investigated
in these samples, a strong direct correlation was observed
between RCRu and FMRP levels but not FMR1 mRNA levels
(Figure 4).
Further studies are warranted by including either a wider
array of outcomes or more subjects, however, these results are
consistent with the association between bioenergetics and FMRP
protein expression rather than to FMR1 transcript levels.
Zn Concentrations, Bioenergetics, and
Shank3 Deficiencies in KI Brain
The bioenergetic deficits observed in brains from KI mice were
similar to those reported in previous studies performed on
primary dermal fibroblasts from older premutation carriers
(Napoli et al., 2011). That study ascribed the bioenergetic
deficits to altered ZnT6 protein level and lower transport
of cytoplasmic Zn (Napoli et al., 2011), which resulted
in deficient Zn-mediated import/processing of nuclearly-
encoded mitochondrial subunits (Napoli et al., 2011). As a
result of the defective Zn-dependent processing/import of
nuclear DNA (nDNA)-encoded mitochondrial proteins, higher
ratios of precursor-to-mature mitochondrial proteins were
observed in fibroblasts and brain samples of premutation
carriers.
To test whether the import/processing of nDNA-encoded
mitochondrial proteins was also affected in the KI mouse model,
providing an explanation for the observed defects in OXPHOS,
we evaluated the protein expression levels of mature and
precursor cytochrome c oxidase subunit IV (CCOIV, Figure 5)
in brains from WT and KI mice. The CCOIV Precursor-to-
Mature ratios (P:M) were significantly increased in hippocampus
(PND21 and PND210) and cerebellum (PND21) of KI mice
(Figure 5), consistent with our previous reports.
To test for Zn homeostasis, Zn levels in brain were
evaluated in parallel. Lower Zn concentrations were observed in
hippocampus and cerebellum of KI mice at PND21 and lasting
into PND210 for both brain regions (Figure 6). Interestingly,
these regions are the ones with the highest Zn concentrations
(average two-fold of cortex; Figure 6), consistent with their
higher fraction of Zn-containing neurons (Sawashita et al., 1997)
and neuron-to-glia ratios (Napoli et al., 2012). In agreement
with the findings previously obtained with fibroblasts from older
premutation carriers (Napoli et al., 2011), a positive correlation
was also observed between Zn levels andmitochondrial outcomes
(namely, activities of Complex IV and citrate synthase and
coupling; Figure 7). Taken together, these results confirmed the
lower import/processing capacity of nDNA-encoded proteins to
mitochondria in premutation and the occurrence of altered Zn
bioavailability.
Zn deficits are linked not only to altered mitochondrial
protein import (Tokatlidis et al., 2000; Napoli et al., 2011)
but also to dysregulation of Shank2/3 scaffolding (Grabrucker
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FIGURE 5 | Protein expression of precursor and mature CCOIV in brains from KI mice. Representative Western blots of CCOIV (precursor and mature
proteins) in hippocampus (A), cerebellum (B) and cortex (C) of WT and KI mice. The densitometry for all the samples is also shown. Data were expressed as Arbitrary
Densitometry Units and reported as mean ± SEM. Mature form of CCO4 was normalized by GAPDH. Data are reported as mean ± SEM, n = 3–5 per genotype per
time point, ran in triplicates. Statistical analysis was performed by Two-way ANOVA, followed by Tukey post-hoc test for multiple comparisons. Statistically significant
differences between WT and KI are indicated by asterisks as follows. Hippocampus: *p = 0.0416; ***p = 0.0002; ****p < 0.0001. Cerebellum: *p = 0.0212 for mature
CCO at PND21; *p = 0.0197 for P:M at PND21. Statistically significant differences among time points are indicated by letters as follows. Hippocampus: p = 0.0002
(a), p = 0.0172 (b), p = 0.0013 (c), p = 0.0047 (d), p = 0.0086 (e), p < 0.0001 (f ), p = 0.0003 (g). Cerebellum: p = 0.0459 (a). Cortex: p = 0.0391 (a), p = 0.0113 (b).
Further statistical details on the genotype, age, and genotype × age effect can be found in Table 3. (D) Uncropped version of the Western blot image showing the
intensity and mobility of the precursor band relative to the mature protein. The observed molecular weights for the CCOIV precursor and mature forms were,
respectively, 20.0 and 17.5 kDa, as extrapolated by the Molecular Weight markers with the use of the Carestream software. This 2.5 kDa difference was close to the
theoretical calculated molecular weight (2.4 kDa) of the 22 residues of amino acids (MLATRVFSLVGKRAISTSVCVR) present in the precursor form, which is cleaved by
mitochondrial matrix peptidases (Isaya et al., 1991) to produce the mature mitochondrial form of the protein (UniProtKB P13073). Asterisk in the immunoblot image of
hippocampus (panels A and D) denotes a 90 CGG KI sample. Densitometry data for this sample have not been included in the averages for KI. For cortex, samples
were run in two separate gels (PND9 and PND21-210). AUD, Arbitrary Units of Densitometry.
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FIGURE 6 | Brain Zn concentrations in WT and KI mice. Total Zn levels were measured in whole hippocampus, cerebellum and cortex homogenates from WT
and KI mice. Data are shown as mean ± SEM, n = 3–6 individuals per genotype, per time point, ran individually. Statistical analysis was performed by Two-way
ANOVA, followed by Tukey’s HSD post-hoc test for multiple comparisons. Statistically significant differences between WT and KI at individual time-points are indicated
by asterisks as follows: Hippocampus: *p = 0.0425; **p = 0.0070; Cerebellum: *p = 0.0158; ***p = 0.0003. Statistically significant differences among time points are
indicated by letters as follows: p = 0.0190 (a), p = 0.0144 (b), p = 0.0003 (c). Further statistical details on the genotype, age, and genotype × age effect can be found
in Table 3.
et al., 2014). Indeed, Shank3 transcript—as actin transcript—
has been identified as one of the main mRNAs interacting
with FMRP (Darnell et al., 2011) and both FMRP and
FMR1 mRNA are normally present in ribosomes associated
to postsynaptic dendritic sites, location shared by Shank3
(Weiler et al., 1997).
Deficits in Shank3 protein expression—evaluated by
Western blots—were noticeable at PND9, PND21, and PND210
in hippocampus and cerebellum from KI mice (Figure 8
and Supplementary Figure 1). These results are consistent
with other studies reporting Shank3 protein expression
being brain-region/cell-type specific and developmentally
regulated (Wang et al., 2014). Of note, although Shank3 is a
postsynaptic density protein, several studies have shown that
Shank3 expression pattern in whole brain areas mirrors that
observed at the synaptic regions (Han et al., 2013; Kouser
et al., 2013) providing support for the Shank3 expression
in total homogenates from brain regions. Furthermore,
the amount of tissue collected from each pup, especially at
early time points—i.e., PND9 and PND21—would not have
been sufficient as starting material for postsynaptic density
preparations.
Given that Zn deficits were observed after those in Shank3,
it could be inferred that the reduced levels of FMRP at early
time points affects mainly Shank3 translation whereas later,
both Shank3 protein expression and Zn-dependent scaffolding
seem affected. In brains of WT and KI mice, statistically
significant positive correlations were noted between FMRP
and Shank3 (Figure 8C), FMRP and Zn levels (Figure 7B)
and between Shank3 and Zn levels (Figure 7C), reinforcing
the concept of the crosstalk between FMRP, Shank3, and Zn
homeostasis.
Interaction between Genotype and Age on
FMRP Levels, Bioenergetics, Zn, and
Shank3 in Brains of WT and KI Mice
To test the putative interaction between genotype and age, a Two-
way ANOVA analysis was performed for each of the outcomes
tested at different time-points (Table 3). A statistically significant
genotype × age interaction was observed in hippocampus for
FMRP, most of the mitochondrial outcomes tested (five of eight;
NADH oxidase activity, uncoupling, citrate synthase activity,
and ATPB and COXIV expression), and Shank3, whereas in
cerebellum the interaction was statistically significant for FMRP,
only onemitochondrial outcome (COXIV), Zn levels and Shank3
(Table 3). In cortex, the interaction of age and genotype was
statistically significant only for FMRP levels (Table 3). Thus, the
tissue that showed the most evident gene × age interaction was
hippocampus, followed by cerebellum and then cortex (Table 3).
Simple main effect analysis showed that the overall changes
observed in hippocampus and cerebellum could be equally
attributed to genotype and age, whereas in cortex age had a more
prominent effect (Table 3).
In terms of outcomes, FMRP expression was the only
parameter that showed a strong interaction between genotype
and age in all three-brain regions, with a bigger contribution of
genotype than age (Figure 1 and Table 3). Differences recorded
in mitochondrial outcomes appeared to be determined by both
genotype and age in hippocampus, while age played a bigger
role in cerebellum and cortex (Figure 2 and Table 3). Differences
observed in Zn levels in hippocampus and cerebellum seemed
mainly due to genotype more than age (Figure 6 and Table 3).
Finally, Shank3 expression seemed to be influenced by genotype
and age in hippocampus and cerebellum (Figure 8 and Table 3),
and mainly by age in cortex. Taken together, this analysis
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FIGURE 7 | Correlations among Zn levels, selected mitochondrial outcomes, and protein expression of FMRP and Shank3, in brain of WT and KI mice.
A significant direct correlation was noted between average Zn levels and activities of CCO and CS and RCR for all the time points analyzed (A). CCO and CS activities
were expressed as nmol × (min × mg protein)−1. CCO activity has been normalized to citrate synthase and multiplied by 100. All the other mitochondrial outcomes
did not show a correlation with Zn. A direct correlation was also observed between Zn levels and both FMRP and Shank3 protein expression (individual values) in
brains of WT and KI when all time points were combined (B,C). Dotted lines illustrate the 95% CI obtained with WT and KI values.
indicates a stronger effect of the KI genotype than age on the
outcomes evaluated in hippocampus, about equal for cerebellum
and mostly age-dependent effects in cortex.
Altered ZnT Gene Expression in Lactating
Mammary Glands from KI Dams
While some of the Zn, Shank3, and mitochondrial deficits
lasted into PND210 in hippocampus and cerebellum (Figures 2–
8), the finding that most of the mitochondrial outcomes were
significantly different at PND21 (at the end of the nursing period)
and that some amelioration was observed between PND21 and
PND210 in cortex and cerebellum, suggested that lactation
(nursing from KI dams vs. post-weaning diet constituted
by vitamin- and mineral-balanced murine chow) might have
compounded the early deficits. Due to the unsuccessful attempts
to collect sufficient murine milk to evaluate Zn levels or any
other biochemical analyses, as a surrogate for Zn homeostasis
we tested the gene expression of ZnT4 and ZnT6 in lactating
mammary glands from control and KI dams. ZnT4 and ZnT6
gene expression was evaluated by PCR, followed by separation of
the products in a 1.3% agarose gel, visualized by using ethidium
bromide. (Commercially available dual-labeled probes for these
transporters resulted unspecific).
In lactating mammary glands from WT dams, both ZnT4
and ZnT6 (normalized to GAPDH) were expressed with a ratio
of ZnT6/ZnT4 equal to 15 (Figure 9A). The gene expression
of both ZnTs was significantly higher (two-fold) in KI than
WT, with no significant changes in the ZnT6/ZnT4 expression
ratio compared to WT (Figure 9B). These results suggested
a disrupted ZnT expression, which may affect Zn eﬄux in
milk, and as a consequence, the Zn status of the suckling
pups.
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FIGURE 8 | Brain Shank3 protein levels in WT and KI mice. (A) Western blots for Shank3 protein expression levels in hippocampus, cerebellum, and cortex were
performed at PND 9, 21, and 210 from WT (white) and KI (black) mice as described in details in the Materials and Methods Section. Further, images taken with
acetone-precipitated samples and normalized by either tubulin or GADPH are found under Supplementary Figure 1. (B) Densitometry data is shown as mean ± SEM,
n = 4–5 individuals per genotype, per time point, ran individually. Statistical analysis was performed by two-way ANOVA, followed by Tukey’s HSD post-hoc test for
multiple comparisons. Statistically significant differences between WT and KI are indicated by asterisks as follows: Hippocampus: **p = 0.0054; Cerebellum: ****p <
0.0001. Statistically significant differences among time points are indicated by letters as follows: p = 0.0074 (a), p = 0.0267 (b), p < 0.0001 (c, e, f ), p = 0.0217(d),
(Continued)
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FIGURE 8 | Continued
p = 0.0041 (g). Further, statistical details on the genotype, age, and genotype × age effect can be found in Table 3. (C) Correlation between FMRP levels and Shank3
protein expression in brain of WT and KI mice. Both proteins have been normalized by tubulin, used as loading control. Shown are individual data points collected in
cerebellum, hippocampus, and cortex of WT and KI mice at PND9, PND21, and PND210. PND210 is shown in a separate plot due to the difference in protein
expression of both FMRP and Shank3 at this time point, relative to the previous ones. Dotted lines are 95% CI constructed with WT and KI values. AUD, Arbitrary
Units of Densitometry.
TABLE 3 | Effect of genotype, age, and genotype × age interaction on outcomes evaluated in hippocampus, cerebellum, and cortex of WT and KI mice.
Genotype × age interaction Genotype effect Age effect
HIPPOCAMPUS
FMRP F (2, 17) = 23.42 F (1, 17) = 105.3 F(2, 17) = 16.24
p < 0.0001 p < 0.0001 p = 0.0001
NADH oxidase F (2, 18) = 8.466 F (1, 18) = 2.435 F (2, 18) = 17.12
p = 0.0026 p = 0.0464 p < 0.0001
Succinate oxidase F (2, 19) = 0.6392 F (1, 19) = 6.180 F (2, 19) = 16.02
p = 0.5387 p = 0.0224 p < 0.0001
Cytochrome c oxidase F (2, 18) = 1.099 F (1, 18) = 5.245 F (2, 18) = 2.915
p = 0.3545 p = 0.0343 p = 0.0801
RCR F (2, 22) = 9.284 F (1, 22) = 27.45 F (2, 22) = 8.578
p = 0.0012 p < 0.0001 p = 0.0018
Citrate synthase F (3, 47) = 1.307 F (1, 47) = 2.162 F (3, 47) = 8.239
p = 0.283 p = 0.1481 p = 0.0002
ATPB F (2, 15) = 26.74 F (1, 15) = 214.1 F (2, 15) = 39.95
p < 0.0001 p < 0.0001 p < 0.0001
COXIV F (2, 15) = 2.362 F (1, 15) = 3.582 F (2, 15) = 34.88
p = 0.1283 p = 0.0779 p < 0.0001
COXIV (P:M) F (2, 15) = 30.14 F (1, 15) = 78.45 F (2, 15) = 23.12
p < 0.0001 p < 0.0001 p < 0.0001
[Zn] F (2, 17) = 2.588 F (1, 17) = 19.94 F (2, 17) = 7.303
p = 0.1045 p = 0.0003 p = 0.0051
Shank3 F (2, 20) = 2.559 F (1, 20) = 16.50 F (2, 20) = 10.23
p = 0.1024 p = 0.0006 p = 0.0009
CEREBELLUM
FMRP F (2, 15) = 4.768 F (1, 15) = 28.64 F (2, 15) = 13.16
p = 0.0250 p < 0.0001 p = 0.0005
NADH oxidase F (3, 48) = 1.471 F (1, 48) = 0.08211 F (3, 48) = 6.907
p = 0.2341 p = 0.7757 p = 0.0006
Succinate oxidase F (3, 44) = 0.2040 F (1, 44) = 1.196 F (3, 44) = 8.347
p = 0.893 p = 0.2802 p = 0.002
Cytochrome c oxidase F (3, 42) = 1.198 F (1, 42) = 0.1964 F (3, 42) = 2.490
p = 0.3221 p = 0.6559 p = 0.0733
RCR F (3, 40) = 1.493 F (1, 40) = 4.457 F (3, 40) = 1.044
p = 0.2312 p = 0.0411 p = 0.3835
Citrate synthase F (3, 57) = 7.890 F (1, 57) = 0.9931 F (3, 57) = 43.11
p = 0002 p = 0.2323 p < 0.0001
ATPB F (2, 12) = 1.194 F (1, 12) = 7.348 F (2, 12) = 5.603
p = 0.3427 p = 0.0219 p = 0.0233
COXIV F (2, 12) = 5.355 F (1, 12) = 4.313 F (2, 12) = 4.394
p = 0.0262 p = 0.0645 p = 0.0427
COXIV (P:M) F (2, 12) = 3.523 F (1, 12) = 8.816 F (2, 12) = 0.3843
p = 0.0695 p = 0.0141 p = 0.6906
(Continued)
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Genotype × age interaction Genotype effect Age effect
[Zn] F (2, 11) = 12.09 F (1, 11) = 37.88 F (2, 11) = 13.61
p = 0.0017 p < 0.0001 p = 0.0011
Shank3 F (2, 18) = 4.293 F (1, 18) = 85.27 F (2, 18) = 95.15
p = 0.0299 p < 0.0001 p < 0.0001
Cortex
FMRP F (2, 12) = 9.336 F (1, 12) = 38.50 F (2, 12) = 14.01
p = 0.0036 p < 0.0001 p = 0.0007
NADH oxidase F (3, 41) = 0.2289 F (1, 41) = 0.0008 F (3, 41) = 19.52
p = 0.8757 P = 0.9286 p < 0.0001
Succinate oxidase F (3, 46) = 0.09088 F (1, 46) = 1.045 F (3, 46) = 15.24
p = 0.9647 P = 0.3120 p < 0.0001
Cytochrome c oxidase F (3, 46) = 0.09514 F (1, 46) = 3.203 F (2, 46) = 12.30
p = 0.9623 p = 0.0801 p < 0.0001
RCR F (3, 45) = 0.2112 F (1, 45) = 4.890 F (3, 45) = 2.388
p = 0.8881 p = 0.0321 p = 0.0813
Citrate synthase F (3, 55) = 1.983 F (1, 55) = 1.983 F (3, 55) = 213.7
p = 0.1272 p = 0.3405 p < 0.0001
ATPB F (2, 11) = 1.249 F (1, 11) = 0.6066 F (2, 11) = 15.49
p = 0.3246 p = 0.4525 p = 0.0006
COXIV F (2, 12) = 3.819 F (1, 12) = 1.054 F (2, 12) = 12.72
p = 0.0630 p = 0.3313 p = 0.0024
COXIV (P:M) F (2, 12) = 1.018 F (1, 12) = 0.4778 F (2, 12) = 3.047
p = 0.3993 p = 0.5069 p = 0.0976
[Zn] F (2, 12) = 1.913 F (1, 12) = 0.1174 F (2, 12) = 3.011
p = 0.1979 p = 0.7389 p = 0.0947
Shank3 F (2, 12) = 0.4705 F (1, 12) = 1.679 F (2, 12) = 9.085
p = 0.6322 p = 0.2114 p = 0.0019
Statistical parameters reported in the table were calculated by Two-way ANOVA. In bold are statistically significant effects. Between parentheses are values of F(DFn, DFd). Further,
statistical details are reported in the figure legend of each outcome tested.
Studies have shown that Zn deficiency in rodents results in
anorexia (with about 50% of the body weight gained under
physiological conditions), poor hair coat, scaly paws, and
reproductive defects (Brody, 1999), none of which have been
observed in either KI dams or pups, supporting the idea of
a localized Zn homeostasis deficit related to the premutation
(probably linked to the tissue expression of FMRP), rather than a
generalized one.
Detrimental Effect of KI Milk on Brain
Bioenergetics
On the basis of the findings shown thus far we hypothesize
that Zn-deficient milk of KI dams would be detrimental on the
suckling pups’ bioenergetics requirements, whereas milk from
WT dams might rescue some of the deficits observed in the
premutation mice. To test this hypothesis we designed a cross-
fostering experiment in which KI pups nursed onWT dams (WT
milk) and WT pups nursed on KI dams (KI milk; Figure 10).
We tested mitochondrial outcomes at PND21 from WT and KI
in the pups (male hemizygous) nursing on KI milk to elucidate
the effect of KI milk on the brain bioenergetics of WT pups, or
nursing on WT milk to elucidate the effect of WT milk on the
brain bioenergetics of KI pups (Figure 10).
A detrimental effect on brain bioenergetics was observed in
WT pups nursing on KImilk, characterized by significantly lower
mitochondrial outcomes relative to WT pups nursing on WT
milk in all three brain areas, with the highest effect observed
in hippocampus showing, deficits in four of the five measured
outcomes. On average, the most affected outcome was ATP-
dependent oxygen uptake sustained by NAD-linked substrate
(NADH oxidase activity), followed by ATP-dependent oxygen
uptake sustained by an FAD-linked substrate (succinate oxidase
activity), CCO activity, and coupling (Figure 10). Furthermore,
the hippocampus of WT pups nursing on KI milk showed a
significant decrease in mitochondrial mass. Of note, although the
detrimental effects of the KI milk on the mitochondrial outcomes
in WT pups were significant (–29± 8% average of all outcomes),
they were not severe enough to match the deficits observed in
KI pups nursed on KI milk (–46 ± 11%, mean ± SEM). KI
pups nursing on WT milk compared to KI pups nursed on KI
milk exhibited some mitochondrial improvement, as judged by a
partial recovery of succinate oxidase activity in cerebellum (from
60 to 82% ofWT) and complete recovery of succinate oxidase and
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FIGURE 9 | ZnT4 and ZnT6 gene expression in mammary glands from
lactating WT and KI dams. Representative image of the PCR products
(obtained by RT-qPCR as described under Methods) that were separated in a
1.3% agarose gel and visualized with ethidium bromide (A). The fragments
exhibited the expected sizes of 585 bp (ZnT4) and 537 bp (ZnT6). GAPDH
PCR product was separated in a 3% agarose gel electrophoresis with
ethidium bromide resulting in a product of the expected of 107 bp (not shown).
Intensities of ZnT4 and ZnT6 bands were obtained in a Kodak Imager were
normalized by that of GAPDH (B). Bars represent averages ± SEM of 4
individuals/genotype. Statistical analysis was carried out with the Student’s
t-test between WT and KI. *p < 0.05.
coupling in cortex (Figure 10). None of the measured outcomes
showed a significant recovery in hippocampus (Figure 10).
The effect of the diet (KI vs. WT milk) and genotype on
mitochondrial outcomes was evaluated by Two-way ANOVA
(Table 4). A significant milk type × genotype interaction on
bioenergetics was observed in all brain regions, with the
main effects being attributed to genotype in hippocampus and
cerebellum, and to both genotype and milk type in cortex
(Table 4).
Taken together these results suggest that, despite the presence
of a susceptible genetic background conferred by the FMR1
premutation, brain mitochondrial outcomes were modulated by
a nutritional intervention (KI milk) mainly in cortex, the least
Zn-enriched brain region. While the impact of cross-fostering
on offspring’s brain bioenergetics could not be explained by
differences in caloric intake because there were no statistical
differences in body weight gain or brain weight gain between
the two groups (not shown), the changes in mitochondrial
brain OXPHOS in both WT and KI mice were consistent with
a compounding effect of an altered Zn homeostasis in milk
from premutation carriers (Table 4). While WT pups nursing
on KI milk resulted in MD (hippocampus and cerebellum), KI
pups nursing on WT milk improved some of the mitochondrial
outcomes (cortex). The lack of a significant improvement
in all of the brain regions tested could be explained by
their different brain Zn requirements (Sawashita et al., 1997),
limitations of a non-optimized intervention on a specific genetic
background, or inability of achieving a complete recovery of
some of the components involved in post-synaptic scaffolding
and bioenergetics beyond PND21.
Zn Deficits in Breast Milk from Premutation
Carriers
To complement and further confirm the experiments performed
with the premutation mouse model, experiments were extended
to test the quality of milk from lactating women carrying
the premutation. Zn concentrations were determined in
mature human milk [i.e., 8–20 weeks of lactation (Worth
et al., 1981)] from asymptomatic premutation women (milk
CGG repeats = 63–119) and age-matched controls (Table 5).
Furthermore, we tested selected Zn-associated outcomes, namely
activity of milk alkaline phosphatase (ALP), a Zn-requiring
enzyme that contributes with 20% of total milk Zn (Fransson
and Lonnerdal, 1984), and concentrations of lactose, whose
biosynthesis is dependent on the Zn-requiring enzyme β-1,4-
galactosyltransferase (McCormick and Kelleher, 2012), the rate
limiting enzyme in the lactose biosynthetic pathway (Jagoda and
Rillema, 1991).
Milk from healthy donors had an average Zn concentration
of 26 ± 2 µM (1.7 ± 0.1 mg/l), within the normal range
reported before [1.0–1.7 mg/l at 3–5 months of lactation
evaluated by atomic absorption spectrometry (Krebs et al.,
1995)], with 86% of the Zn being in the labile form. In agreement
with data previously reported (Nagra, 1989; Krebs et al.,
1995), milk Zn concentrations from control and premutation
women were reciprocally correlated with the postpartum period
(Figure 11A), following a pseudo-first order kinetics with a
biological half-life of 8 weeks (Figure 11). Although 10 of the 25
control donors were taking vitamins and mineral supplements
(including Zn) during lactation, no significant differences in
Zn concentrations were observed between these two groups, in
agreement with the observed lack of correlation between milk
or plasma Zn concentrations and maternal Zn intake (Krebs
et al., 1995). In samples from premutation carriers, the average
milk Zn concentration at 3–5 months of lactation was 56% of
control values (14 ± 3 µM; p = 0.020). Specifically, milk Zn
concentrations from two carriers at 8–9 lactation weeks and
from one carrier at 19–20 weeks were significantly lower than
the 95% CI (Figure 11A, Table 6). Zn levels in the remaining
premutation milk samples, obtained after week 15, followed
the decrease observed in control milk (Figure 11A, Table 6).
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FIGURE 10 | Changes in mitochondrial outcomes in hippocampus, cerebellum and cortex of suckling WT and KI pups nursed on WT or KI dams. At
birth, KI pups (n = 24) and WT pups (n = 24) were foster-nursed either on KI dams or WT dams, six pups on each dam. After 21 days, mitochondria were isolated
from cortex, cerebellum, and hippocampus and activities of NADH oxidase, succinate oxidase, cytochrome c oxidase, and citrate synthase and RCR were evaluated
as described in the Methods section. wt/wt =WT pups nursing on WT milk; ki/ki = KI pups nursing on KI milk. Circles represent WT pups, squares represent KI pups.
White symbols represent WT milk and black symbols represent KI milk. Upward or downward arrows represent improvement or worsening, respectively, upon nursing
on WT milk or KI milk. Activities (NADH oxidase, succinate oxidase, cytochrome c oxidase) were expressed as nmol × (min × mg protein)−1, normalized by citrate
(Continued)
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FIGURE 10 | Continued
synthase activity and multiplied by 1000. Data are shown as mean ± SEM (from technical replicates of pooled samples). Statistical analysis was performed by
Two-way ANOVA, followed by Tukey’s post-hoc test for multiple comparisons. The p values are as follows. Hippocampus: p < 0.0001 (a, b, c, g, i, p, q), p = 0.0004
(d, o), p = 0.0002 (e, f ), p = 0.0025 (h), p = 0.0008 (j), p = 0.0027 (k), p = 0.0006 (l), p = 0.0262 (m), p = 0.0082 (n); Cerebellum: p = 0.0296 (a), p = 0.0301 (b), p =
0.0039 (c), p < 0.0001 (d, g, h, i, j, k, l, m, n, o, p), p = 0.0023 (e); p = 0.0086 (f ); Cortex: p < 0.0001 (a, b, c, d, e, f ), p = 0.0047 (g), p = 0.0468 (h). Further
statistical details on the genotype, age, and genotype × age effect can be found in Table 4.
TABLE 4 | Effect of genotype, diet, and genotype × diet interaction on outcomes evaluated in hippocampus, cerebellum, and cortex of cross-fostered WT
and KI pups.
Genotype × diet interaction Genotype effect Diet effect
HIPPOCAMPUS
NADH oxidase F (1, 11) = 58.03 F (1, 11) = 57.52 F (1, 11) = 32.05
p < 0.0001 p < 0.0001 p = 0.0001
Succinate oxidase F (1, 11) = 20.96 F (1, 11) = 20.49 F (1, 11) = 14.15
p = 0.0008 p = 0.0009 p = 0.0031
Cytochrome c oxidase F (1, 11) = 29.96 F (1, 11) = 1.501 F (1, 11) = 97.53
p = 0.0002 p = 0.2462 p < 0.0001
RCR F (1, 11) = 0.1242 F (1, 11) = 39.29 F (1, 11) = 1.039
p = 0.7312 p < 0.0001 p = 0.3298
Citrate synthase F (1, 11) = 10.35 F (1, 11) = 26.72 F (1, 11) = 67.89
p = 0.0082 p = 0.0003 p < 0.0001
CEREBELLUM
NADH oxidase F (1, 11) = 0.6863 F (1, 11) = 15.68 F (1, 11) = 1.384
p = 0.4250 p = 0.0022 p = 0.2642
Succinate oxidase F (1, 11) = 12.75 F (1, 11) = 97.54 F (1, 11) = 5.300
p = 0.0044 p < 0.0001 p = 0.0419
Cytochrome c oxidase F (1, 11) = 905.1 F (1, 11) = 69.16 F (1, 11) = 403.2
p < 0.0001 p < 0.0001 p < 0.0001
RCR F (1, 11) = 14.28 F (1, 11) = 1146 F (1, 11) = 4.768
p = 0.0031 p < 0.0001 p = 0.0515
Citrate synthase F (1, 11) = 1.582 F (1, 11) = 0.8701 F (1, 11) = 0.3943
p = 0.2290 p = 0.3667 p = 0.5401
CORTEX
NADH oxidase F (1, 11) = 98.63 F (1, 11) = 4.235 F (1, 11) = 0.5049
p < 0.0001 P = 0.0641 p = 0.4921
Succinate oxidase F (1, 11) = 34.47 F (1, 11) = 61.96 F (1, 11) = 149.0
p = 0.0001 P < 0.0001 p < 0.0001
Cytochrome c oxidase F (1, 11) = 16.45 F (1, 11) = 109.7 F (1, 11) = 71.65
p = 0.0019 p < 0.0001 p < 0.0001
RCR F (1, 11) = 60.13 F (1, 11) = 44.72 F (1, 11) = 84.89
p < 0.0001 p < 0.0001 p < 0.0001
Citrate synthase F (1, 11) = 2.068 F (1, 11) = 0.1195 F (1, 11) = 0.0441
p = 0.1724 p = 0.7347 p = 0.8367
Statistical parameters reported in the table were calculated by Two-way ANOVA. Outcomes were measured in 24 mice (12 WT and 12 KI). Due to the scarce amount of tissue collected
from hippocampus and cerebellum, material from four animals belonging to the same genotype and nursed from the same dam were pooled. The cross-fostering experiment was
repeated twice, for a total of 48 mice used. In bold are statistically significant effects. Between parentheses are values of F(DFn, DFd). Further, statistical details are reported in the figure
legend of each outcome tested.
Although the sample size is small, the incidence of low Zn
concentration was higher in carriers compared to controls (60%
vs. 24%; test for one proportion p = 0.0595; 95% CI = 0.2307–0.
8824).
The ALP activity in human breast milk from control
donors increased almost linearly from eight to 18–20 weeks, in
agreement with other reports (Chanda et al., 1951; Stewart et al.,
1958; Worth et al., 1981) and with published values (Worth et al.,
1981; Coburn et al., 1992; Figure 11B, Table 6). As observed
with milk Zn concentrations, ALP activities in controls were
not affected by vitamin supplementation. Changes in milk ALP
activity with lactation week from premutation donors paralleled
those of controls, with only one carrier showing a 51% ALP
activity of control values at 19 weeks (Figure 11B, Table 6).
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TABLE 5 | Details of the study population.
Premutation carrier Milk CGG repeats Maternal age at sample Lactation week at
collection (y) sample collection
1 29, 63 38 20
2 20, 80 34 9
3 29, 91 34 16
4 30, 93 23 19
5 29, 119 34 8
MEAN ± SEM
Premutation women 89 ± 9 33 ± 2 14 ± 2
(n = 5)
Control women 27 ± 2 31 ± 1 13.1 ± 0.5
(n = 25) (p = 0.002)
CGG repeats were evaluated by extracting total genomic DNA from milk samples and following the procedure described before (Tassone et al., 2012). The mean CGG for premutation
patients represent that of the longer allele only.
In terms of protein and lactose concentrations, the mean
nutrient composition of milk samples was not different between
controls and premutation individuals and remained fairly
constant throughout the evaluated period, consistent with
published concentrations for controls [[protein] in g/l: this
study = 12.8 ± 0.5, 95%CI 12-13, literature = 12 ± 1.5
(Tudehope, 2013); [lactose] in mM: this study = 205 ± 3
95%CI 199-210, literature= 196± 15 (Nagra, 1989; Mohammad
et al., 2012; Tudehope, 2013)]. However, the incidence of
either low protein or low lactose concentrations was higher
in premutation carriers than controls (Table 6). Interestingly,
these observations are consistent with the findings obtained in
HC11 cells in which overexpression of ZnT4 lowers both β-1,4-
galactosyltransferase activity (McCormick and Kelleher, 2012)
and lactose concentration by compromising the incorporation of
Zn into Zn-requiring proteins.
Taken together, these results show lower milk Zn
concentrations in premutation women, consistent with an
altered Zn homeostasis as observed in mammary glands from
KI dams, supporting the idea that adequate gene expression of
ZnT4 and ZnT6 may be required during the switch from the
non-lactating to the lactating condition to support normal Zn
eﬄux into milk.
DISCUSSION
Our study reports the contribution of FMRP protein expression
to the development of brain bioenergetics, cytoskeleton
structure, and post-synaptic scaffolding protein Shank3 in FMR1
premutation carriers at early stages of life. In support of this
concept, we found (i) mitochondrial deficits at PND0 in isolated
neurons from hippocampus, cerebellum and cortex of KI pups
likely reflecting an embryonic (pre-natal) FMRP-dependent
dysfunction; (ii) deficits in bioenergetics, Zn concentrations and
Shank3 protein, mainly in hippocampus and cerebellum (Zn-rich
brain areas) of KI pups at PND21, with some of these deficits
lasting into adulthood; and (iii) defective import/processing of
nDNA-encoded mitochondrial subunits secondary to impaired
Zn homeostasis. A strong genotype × age interaction was
observed for most of the outcomes tested in hippocampus and
cerebellum, whereas in cortex, age played a major factor.
The effect of maternal milk Zn on offspring bioenergetics
highlights the influence of genetics × nutrition on the
premutation supported by the altered gene expression of
ZnT6/T4 in lactating KImammary glands, the KImilk-dependent
detrimental effect on KI and WT brain bioenergetics, and the
lower milk Zn content in breast milk from lactating premutation
women. A highly significant milk type × genotype interaction
was observed for all three-brain regions being cortex the most
influenced.
Brain Zn concentrations change with age, reflecting its
function as a neuromodulator and as a required element for
brain development (Sawashita et al., 1997), especially in regards
to synaptic transmission and bioenergetics (Ho et al., 2003;
Kogan et al., 2008; Grabrucker et al., 2014; Hara et al., 2014;
Picard and McEwen, 2014). Our study is consistent with the
reported detrimental effect of milk Zn deficiency on perinatal
outcomes in the lethal milk (lm) mice (Huang and Gitschier,
1997), and in agreement with the proposed role of FMRP as
modulator of synaptogenesis through actions on cytoskeletal
proteins, by interacting with specific mRNAs [such as Shank3
or actin (Brown et al., 2001; Darnell and Richter, 2012; Han
et al., 2013)] or via the Rac1 pathway (Bardoni and Mandel,
2002). The lower milk Zn concentration found in premutation
women and the altered ZnT4/ZnT6 gene expression in lactating
KI murine mammary gland may account for the effect of KI
milk on the brain bioenergetics of both WT and KI offspring,
but more evident in KI pups. Given the heavy reliance of brain
on mitochondrial ATP as well as on de novo synthesis of Krebs
cycle-associated neurotransmitter amino acids [i.e., Glu, Asp,
and GABA (Butterworth and Heroux, 1989; Navarro et al.,
2008)], mitochondrial and synaptic scaffolding deficits are likely
to increase the risk for some of the neurological symptoms
observed in pediatric carriers. Indeed, altered brain bioenergetics
and those of the post-synaptic scaffolding protein Shank3 during
perinatal periods may explain the abnormal behavior observed
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FIGURE 11 | Role of milk Zn in brain bioenergetics and synapse scaffolding in premutation carriers. Milk-Zn concentrations followed a pseudo-first order
kinetics over the lactation period (A). Milk Zn concentrations from control and premutation donors decreased with the post-partum period, ranging from 30 ± 3 µM at
6–8 weeks to 15 ± 2 µM at 18–20 weeks. The LN values of the Zn concentrations (in µM) were plotted against lactation week. The published values were obtained
from Nagra et al. (Nagra, 1989) and shown as white squares. Regression parameters are as follows: for published [Zn], r2 = 0.997, y = −0.09x + 4.3; for this study,
r2 = 0.647, y = −0.07x + 4.0. P value for slopes = 0.458; P value for intercepts = 0.986. ALP activity [expressed as nmol × (min × mg protein)−1] in human breast
milk from control donors increased linearly from 8 to 18–20 weeks (B). The average ALP activity of controls was 3.3 ± 0.3 nmol × (min × mg protein)−1 or 46 ± 1
µmol × (min × l)−1 and within reported values [40 to 60 µmol × (min × l)−1; (Worth et al., 1981; Coburn et al., 1992)]. Linear regression analyses were performed
with control values (reported as mean ± SEM) for both outcomes (r2 = 0.638 and 0.639 for Zn concentration and ALP activity, respectively). The 95% CIs performed
with control values are shown with dotted lines. Individual premutation carriers’ values for Zn concentrations and ALP activities are shown in Table 5. ALP activities in
controls were not affected by vitamin and mineral supplementation [supplemented: 3.7 ± 0.4 vs. not supplemented: 3.2 ± 0.4 nmol × (min × mg protein)−1; p =
0.624]. A model integrating experimental data based on altered Zn homeostasis, mitochondrial dysfunction [current study and (Ross-Inta et al., 2010; Napoli et al.,
2011)], and the putative effect of defective synaptic scaffolding in premutation individuals is shown in (C). During lactation, Zn uptake is exerted by ZIP5, 8 and 10,
then excreted to milk via ZnT4/ZnT2 with a lower flux through ZnT6 (ZnT10) in the Golgi [Adapted from (Kelleher et al., 2012)]. The presence of the CGG expansion in
FMR1, as it is the case with premutation carriers, may ensue in a lower expression of FMRP, which may affect the cytoskeleton (e.g., actin, Shank3), and the
expression or function of membrane transporter such as ZnT4/T6. This situation would ensue in the suboptimal delivery of Zn into milk, mitochondrial dysfunction, and
synaptic dysregulation. The arrows indicate the direction of Zn transport from maternal blood to milk.
in KI mice later in life [12 and 24 weeks; (Van Dam et al., 2005;
Hunsaker et al., 2009, 2012)], similar to the spatial processing
defects observed in humans with FXTAS (Hunsaker et al., 2012).
While the relative contribution of RNA sequestration of
essential factors, low FMRP expression and RAN translation
(of the toxic FMRPolyG) to the premutation pathology is
still unknown, this study supports the notion that that lower
levels of wild-type FMRP [as observed in this study and
most premutation carriers (Kenneson et al., 2001), with or
without the generation of aberrant FMRP isoforms (Todd et al.,
2013)] may provide a disrupted cellular background that affects
cytoskeleton/scaffolding (actin, Shank3) and Zn homeostasis
allowing environmental factors (e.g., quality of the breast milk)
to further affect synaptogenesis and mitochondrial function early
in life (Figure 11C).
In support of this concept, FMRP protein expression—and not
FMR1 mRNA levels—correlates positively with mitochondrial
outcomes (ATP-driven oxygen uptake and coupling) in both
the KI mouse model and primary dermal fibroblasts from
premutation and full mutation carriers. Furthermore, the
incidence of neurodevelopmental disorders like ASD, ADHD,
anxiety, and other types of psychopathologies (Farzin et al.,
2006; Tassone et al., 2012; Winarni et al., 2012; Wong et al.,
2012; Battistella et al., 2013; Chonchaiya et al., 2013) observed
in young carriers seem to follow the FMRP protein expression
[e.g., incidence of ASD in FXS is 60% (Garcia-Nonell et al., 2008;
Harris et al., 2008; D’Hulst et al., 2009; Zingerevich et al., 2009;
Hagerman et al., 2010) and in premutation carriers is ∼15%
(Farzin et al., 2006; Chonchaiya et al., 2013)]. In this regard, and
consistent with our findings, the expression levels of a subset of
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TABLE 6 | Characteristics of mature breast milk from premutation individuals.
Premutation carrier [Zn] (µM) [mg/l] ALP activity [nmol × (min × mg)−1] [Protein] (mg/ml) [Lactose] (mM)
1 13 ± 1 7.9 ± 0.6 12.2 ± 0.4 213 ± 3
[0.84 ± 0.08]
2 8 ± 2 2.9 ± 0.3 6.0 ± 0.1 160 ± 4
[0.50 ± 0.05]
3 25 ± 2 7.3 ± 1.0 11.4 ± 0.4 231 ± 1
[1.67 ± 0.13]
4 9 ± 1 2.1 ± 0.3 17.7 ± 0.7 196 ± 2
[0.57 ± 0.09]
5 17.2 ± 4 1.5 ± 0.1 19.9 ± 2.0 208 ± 1
[1.13 ± 0.91]
(Mean ± SEM) 14 ± 3 4 ± 2 13 ± 3 202 ± 13
[0.94 ± 0.21]
<95% CI 3 of 5 1 of 5 2 of 5 2 of 5
p-value 0.001 n.s. 0.054 0.054
Controls (mean ± SEM) 26 ± 2 4 ± 1 12.8 ± 0.5 205 ± 3
[1.68 ± 0.12]
95% CI 12–13 199–210
For samples from premutation carriers, each outcome was expressed as mean ± SD, reflecting technical variability of triplicates. In bold, values below the 95% CI calculated with control
values. For Zn concentrations and ALP activities, outcomes that change with the lactation week, the 95% CIs are shown in Figures 9A,B. No significant correlation was obtained
between lactation week and lactose or protein concentrations, thus the 95%CIs were calculated using all control data regardless of lactation week. The p-values correspond to the test
for one proportion. n.s., not significant. A post-hoc analysis to calculate the power of the analysis for the means of milk-Zn concentration from each group was 1.00, whereas for all
others was 0.504 or lower (G*power software; v. 3.0.10).
miRNAs involved in learning, memory and autistic behavior have
been shown to be deregulated in FXTAS (Zongaro et al., 2013;
Nguyen et al., 2016).
While additional studies will be necessary to estimate
Zn requirements for breast-fed only premutation carriers’
babies and assess potential benefits of Zn-fortified milk (while
controlling for confounding factors and monitoring for potential
adverse effects), our findings emphasize that early nutritional
interventions to prevent MD seem critical for the management
of premutation carriers at high risk of developing emotional
and neurological/cognitive problems (including autism) and/or
FXTAS later in life (Tassone et al., 2012; Winarni et al., 2012;
Wong et al., 2012; Battistella et al., 2013; Kim et al., 2013).
This is largely relevant considering the independence of milk-
Zn concentrations on maternal diet (Moore et al., 1984; Krebs
et al., 1995), and consistent with the fact that infants born to the
lowest milk Zn-producingmothers (among other feeding factors)
are more stunted than infants of women with higher milk Zn
concentrations (Krebs et al., 1995; Umeta et al., 2000; Krebs and
Hambidge, 2007).
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